CorMedix (NASDAQ: CRMD) reported Q4 EPS of $0.16, $0.69 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $128.6 million versus the consensus estimate of $128.48 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.